Company intelligence / Profile preview

Cure.ai

Mumbai, Maharashtra, Indiacureai.co.uk ↗

Ownership: Private
Employees: ~200
Development stage: Commercial

Overview

Qure.ai’s AI-driven medical imaging solutions are deployed globally with real-world evidence supporting their use in early diagnosis of TB, stroke, lung cancer, and more. The company has received FDA clearances for several products. Collaborations with AstraZeneca aim to screen millions of patients by 2025. Their technology integrates with both new and legacy radiology hardware to enable rapid triage and diagnosis in clinical settings.

Therapeutic areas: OncologyRheumatologyCardiovascularNeurologyInfectious Diseases
Modalities: Device (AI-powered medical imaging analysis)
Industry: Medical Imaging

Partnerships

AstraZeneca (“EDISON Alliance’s 1 Billion Lives Challenge” partnership to screen millions of patients)Medtronic India (collaboration on stroke care workflow improvement)

Beyond the preview

Go deeper on Cure.ai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cure.ai.

Explore the full profile